BUSINESS
India’s healthcare deals top Rs 10,000 crore in Q2FY26 as hospitals, diagnostics lead expansion: EY
Private equity and strategic investors continued to chase scalable regional platforms with strong clinical depth and technology‑enabled models, EY report said.
BUSINESS
Sun Pharma terms $10-billion Organon buy report as 'speculative'
A report on Monday said that Sun Pharma is evaluating a takeover of Organon & Co. in a transaction that could be valued at about $10 billion including debt, a move that would mark the biggest overseas acquisition ever by an Indian drugmaker.
BUSINESS
We can launch a new drug every 2 or 3 years, Wockhardt chairman Khorakiwala
The portfolio stays firmly anchored in antibiotics, an area big pharma abandoned due to low commercial returns, with focus on products that can fight mult-drug resistant infections
BUSINESS
US oversight of Venezuelan oil may unlock Indian pharma dues, revive exports
At its peak, India pharmaceutical exports to Venezuela amounted to $250 million before the country’s economic collapse.
BUSINESS
Zydus Lifesciences' unit Sentynl wins USFDA nod for rare pediatric disease therapy
Clinical trials showed early treatment reduced the risk of death by nearly 80 percent compared to untreated controls, with median overall survival reaching 177 months versus 17.6 months for untreated patients.
BUSINESS
Respiratory medicine volumes double in December due to poor air quality, seasonal factors
According to the latest PharmaTrac data, the respiratory unit sales rose 5.2% versus 2.6% for the overall IPM, while value growth held firm at 10.1% for respiratory compared with 10.6% for IPM, underscoring a demand-led finish to the year.
BUSINESS
Mounjaro dominates GLP-1 segment that crossed Rs 1000 crore sales in 2025
According to PharmaTrac data., Mounjaro launched in March last year, added Rs.105 crore in December, taking its total sales to Rs.600 crore in sales, reflecting rapid uptake despite hardly any insurance coverage and out‑of‑pocket affordability constraints.
BUSINESS
DKSH eyes India entry via acquisitions, targets specialty segments
The Swiss market‑expansion services group is in talks with potential acquisition targets and expects an entry to take shape over the next 12 to 24 months, Bijay Singh, global head of DKSH’s healthcare business, tells Moneycontrol
BUSINESS
Cipla shares slide 4.5% after USFDA flags compliance gaps at key Lanreotide supplier site
Regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s important complex injectables
HEALTH-AND-FITNESS
New study finds generics as effective as branded drugs at a fraction of the cost
All samples met Indian Pharmacopeia standards for drug content, dissolution, and impurities, with no meaningful quality differences. Mean drug content stood at 99.45 percent overall—101.35 percent for brands versus 99.10 percent for generics.
BUSINESS
Torrent Pharma board gives nod to Rs 12,500-crore bond issue
The company is in the final stages of completing its JB Chemicals buyout, with SEBI approval for the minimum tender offer already secured
BUSINESS
Supriya Lifescience bets on capex, new products to drive next growth phase
We are very much confident that we will be able to achieve our guidance of 20 percent plus growth in revenue, Managing Director Saloni Wagh told Moneycontrol.
BUSINESS
Cough syrup crisis, US trade heat and R&D breakthroughs define Indian pharma’s in 2025
In 2025, the BSE Healthcare Index which is represented by mostly pharma companies underperformed the Sensex, declining approximately 1.5% year to date as of late December, compared to Sensex's positive 8.36% annual gain.
BUSINESS
Government bans high-dose Nimesulide oral formulations over safety concerns
Nimesulide, a non-steroidal anti-inflammatory drug (NSAID), has long been under scrutiny globally for potential liver toxicity and other adverse effects.
BUSINESS
Newly listed Corona Remedies announces major capex at its Bhayla manufacturing site in Gujarat
The expansion, funded entirely through internal accruals, aims to optimize production and maintain high utilization rates—already at 93.58 percent as of March 2025.
BUSINESS
Govt to finalise penicillin import price floor shortly to support domestic API investments under PLI: Sources
The MIP, if approved, may potentially enable domestic capacity to survive the price onslaught of Chinese suppliers and will also make Aurobindo Pharma's investment under India’s Production-Linked Incentive (PLI) scheme viable.
BUSINESS
For India’s weight-loss segment, 2025 is the warm-up, 2026 to be inflection point
While 2025 has been crucial for establishing the clinical credibility of GLP-1 agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro), 2026 will mark the 'patent cliff' that will democratise weight loss in India, transforming a luxury lifestyle treatment into a mass-market commodity.
BUSINESS
'The pill is here': Novo Nordisk get USFDA nod for oral weight-loss therapy
The once-daily tablet of Wegovy is as effective as its blockbuster injectable version, the Danish drug maker said. It plans to launch the pill in the US early January
BUSINESS
Motilal Oswal pumps $72 million into Hyderabad-based medtech Sensa Core
The company will use the capital to expand capacity at a new facility in Hyderabad’s Medical Device Park, aimed at scaling production and introducing next-gen point-of-care products
BUSINESS
Medicover’s India arm aiming for 2026 IPO to unlock value in Swedish giant’s fastest-growing market
The move comes as the hospital chain is set to get its 25th hospital operational, capping a growth sprint during which it has deployed around Rs 2,000 crore over the last seven years to build a 6,000-bed network
BUSINESS
Corex cough syrup gets Cipla boost as Pfizer strikes exclusive India deal
The agreement gives Cipla sole rights to sell and distribute the two Corex variants along with some other drugs Pfizer will continue to manufacture and supply the products
BUSINESS
Narayana Health plans to export high-volume, low-cost care model to UK and beyond
“We’ve built the world’s most efficient healthcare model in India. Now we want to apply that in markets where everyone is insured and cost-cutting is critical,” Vice Chairman Viren Shetty said in an interview to Moneycontrol.
BUSINESS
IHH sets stage for growth, integration as Fortis open offer closes
The completion of the open offers — delayed for years amid litigation tied to the erstwhile Fortis promoters and Daiichi Sankyo — removes a long‑standing uncertainty for IHH’s India plans
BUSINESS
Explainer: Novo Nordisk’s two-brand bet, how Ozempic and Wegovy are carving India’s GLP-1 market
While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, reflecting the company’s effort to capture two massive but different patient pools, sometimes with significant overalap.
